WO2025074328 - USE OF ANTI-SIRP-ALPHA ANTIBODIES TO TREAT CANCER
National phase entry is expected:
Publication Number
WO/2025/074328
Publication Date
10.04.2025
International Application No.
PCT/IB2024/059746
International Filing Date
04.10.2024
Title **
[English]
USE OF ANTI-SIRP-ALPHA ANTIBODIES TO TREAT CANCER
[French]
UTILISATION D'ANTICORPS ANTI-SIRP-ALPHA POUR TRAITER LE CANCER
Applicants **
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
OSE IMMUNOTHERAPEUTICS SA
Inventors
KRETSCHMAR, Gunther
MARZIN, Kristell
PETERSSON, Klas
TOSIEK, Milena Jozefina
Priority Data
63/542,980
06.10.2023
US
63/654,781
31.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3854 | |
| EPO | Filing, Examination, Granting | 28118 | |
| Japan | Filing, Examination, Granting | 3207 | |
| South Korea | Filing, Examination, Granting | 3935 | |
| USA | Filing, Examination, Granting | 11190 |
Total:
50,304
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to the treatment of cancer by using an anti-SIRPα (Signal regulatory protein alpha) antibody or antigen-binding fragment thereof. In particular, the present disclosure relates to a method of using and uses of an anti-SIRPα antibody or antigen-binding fragment thereof to treat cancer including, in a treatment regimen that optionally includes the administration of an additional therapeutic agent.[French]
La présente divulgation concerne le traitement du cancer à l'aide d'un anticorps anti-SIRPα (protéine régulatrice de signal alpha) ou d'un fragment de liaison à l'antigène de celui-ci. En particulier, la présente divulgation concerne une méthode d'utilisation et des utilisations d'un anticorps anti-SIRPα ou d'un fragment de liaison à l'antigène de celui-ci pour traiter le cancer, y compris dans un régime de traitement qui comprend éventuellement l'administration d'un agent thérapeutique supplémentaire.